UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
FOR
THE MONTH OF SEPTEMBER 2023
COMMISSION
FILE NUMBER 001-41084
NeuroSense
Therapeutics Ltd.
(Translation of registrant’s name into English)
NeuroSense
Therapeutics Ltd.
11 HaMenofim Street, Building B
Herzliya
4672562 Israel
+972-9-7996183
(Address of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F
☐
On
September 19, 2023, NeuroSense Therapeutics Ltd. (the “Company”) issued a press release announcing that the European,
Japan, and Israel Patent Offices have granted the Company a key patent relating to “Compositions comprising an
anti-inflammatory drug and a dicer activator for use in treatment of neuronal diseases.” A copy of the press release is filed
herewith as Exhibit 99.1.
This
Report on Form 6-K (other than the paragraph immediately preceding the heading “About NeuroSense” in Exhibit 99.1) is hereby
incorporated by reference into the registrant’s Registration Statements on Form F-3 (File No. 333-269306) and Form
S-8 (File No. 333-262480), to be a part thereof from the date on which this report is submitted, to the extent not superseded by
documents or reports subsequently filed or furnished.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
NeuroSense
Therapeutics Ltd. |
|
|
|
|
By: |
/s/
Alon Ben-Noon |
|
|
Name: |
Alon Ben-Noon |
|
|
Title: |
Chief Executive Officer |
Date:
September 19, 2023
2
Exhibit 99.1
NeuroSense Granted Patents in Europe,
Japan, and Israel for its ALS Drug PrimeC
| ● | Patents valid through 2038 |
| ● | Clinical topline results from Phase 2b ALS trial expected in H2 2023 |
CAMBRIDGE, Mass., Sept. 19, 2023 /PRNewswire/ -- NeuroSense
Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today
announced that the European, Japan, and Israel Patent Offices have granted the Company a key patent relating to “Compositions comprising
an anti-inflammatory drug and a dicer activator for use in treatment of neuronal diseases.” The patents relate to NeuroSense’s
unique fixed-dose combination of ciprofloxacin and celecoxib, two U.S. Food and Drug Administration (FDA) approved drugs that are the
active ingredients in PrimeC, the Company’s lead drug candidate for treating Amyotrophic Lateral Sclerosis (ALS).
Corresponding patents have been issued in the U.S., Canada, and Australia
and are valid through 2038, subject to appropriate maintenance. Additional patent applications relating to the novel formulation of PrimeC
and methods for the treatment of other neurodegenerative diseases using NeuroSense’s platform of combination therapies including
StabiliC and CogniC are pending as well.
“We are pleased to receive this most recent patent grant in Europe,
Japan, and Israel, which adds to our growing IP estate as we expect the clinical read-out from our PARADIGM Phase 2b study towards
year’s end. ALS remains a pressing unmet need, and our unwavering commitment to advancing our program, supported by robust intellectual
property, underscores our dedication to delivering an effective therapy for individuals battling ALS.” stated Alon Ben-Noon, NeuroSense’s
CEO.
About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company
focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes
that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease,
among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available
for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of
related biomarkers, NeuroSense’s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
For additional information, we invite you to visit our website and
follow us on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains “forward-looking statements”
that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words
such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,”
“intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,”
“project,” “target,” “aim,” “should,” “will” “would,” or the negative
of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements
are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that
are difficult to predict and include statements regarding the timing of top-line results of, and the results of, the PARADIGM clinical
trial. Further, forward-looking statements are subject to a number of risks and uncertainties as a result of which actual results could
differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include a delay in the
reporting of top-line results from PARADIGM clinical trial; greater than anticipated costs and expenses; the potential for PrimeC to safely
and effectively target ALS; preclinical and clinical data for PrimeC; the timing of current and future clinical trials, timing for reporting
data; the nature, strategy and focus of the company and further updates with respect thereto; the development and commercial potential
of any product candidates of the company; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities
and Exchange Commission (SEC), including NeuroSense’s Annual Report on Form 20-F filed with the SEC on March 22, 2023. Forward-looking
statements contained in this announcement are made as of this date, and NeuroSense Therapeutics Ltd. undertakes no duty to update such
information except as required under applicable law.
Logo - https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
For further information: Email: info@neurosense-tx.com, Tel: +972 9
799 6183
NeuroSense Therapeutics (NASDAQ:NRSN)
Historical Stock Chart
From May 2024 to Jun 2024
NeuroSense Therapeutics (NASDAQ:NRSN)
Historical Stock Chart
From Jun 2023 to Jun 2024